Vor Biopharma Inc. (VOR) Stock Price & Analysis
Vor Biopharma Inc. (VOR) fell 0.08% to USD 13.28 as of June 10, 2026 at 03:33 UTC, according to Nexqual real-time market data.
VOR last closed at USD 13.29; the session ranged USD 12.58–13.4 on volume of 867,772 shares. Market capitalization is $719.59M, with a 52-week range of USD 3.62–65.8 (NMS). Source: Nexqual, June 10, 2026 at 03:33 UTC.
Key Statistics (as of June 10, 2026 at 03:33 UTC)
| Price | USD 13.28 |
|---|---|
| Change | ▼ 0.08% (down) |
| Previous Close | USD 13.29 |
| Open | USD 13.31 |
| Day Range | USD 12.58 – 13.4 |
| 52-Week Range | USD 3.62 – 65.8 |
| Volume | 867,772 shares |
| Market Cap | $719.59M |
| Exchange | NMS |
Technical Analysis (VOR)
Nexqual's technical model rates VOR "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:33 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.4 (neutral) |
| vs SMA50 | Below (USD 15.18) |
| MACD | -0.47 (negative) |
Analyst Ratings (VOR)
Wall Street analysts rate VOR "Strong Buy" based on 8 analysts, with a mean price target of USD 37.88 (range USD 18–50), per Nexqual as of June 10, 2026 at 03:33 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 37.88 |
| High Target | USD 50 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 8 / 1 / 0 |
Earnings (VOR)
| Next Earnings Date | 2026-08-14 |
|---|---|
| EPS Estimate | USD -0.7 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.73 vs est -0.78 ▲ beat |
| 2025-12-31 | USD 307.53 vs est -1.19 ▲ beat |
| 2025-09-30 | USD -121.63 vs est -4.1 ▼ miss |
| 2025-06-30 | USD -251.2 vs est -11.8 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:33 UTC.
Financials & Fundamentals (VOR)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 31.15 |
| Total Cash | $491.52M |
| Total Debt | $2.94M |
| Free Cash Flow | $-195.77M |
Source: Nexqual, June 10, 2026 at 03:33 UTC.
Financial Health Score (VOR)
Nexqual rates Vor Biopharma Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:33 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $492M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$150M |
| Efficiency | Mixed — No data |
Ownership (VOR)
| Insider Ownership | +4.29% |
|---|---|
| Institutional Ownership | +69.39% |
| Shares Outstanding | 54.19M |
| Float | 43.71M |
| Short % of Float | +10.64% |
Source: Nexqual, June 10, 2026 at 03:33 UTC.
Leadership (VOR)
Vor Biopharma Inc. is led by Jean-Paul Kress (age 60), Chairman, President & CEO, per Nexqual as of June 10, 2026 at 03:33 UTC.
| Chairman, President & CEO | Jean-Paul Kress (age 60) |
|---|---|
| Chief Business Officer & CFO | Sandesh Mahatme L.L.M. (age 60) |
| Scientific Founder & Chairman of Scientific Advisory Board | Siddhartha Mukherjee DPHIL (age 54) |
Major Backers & Investors (VOR)
Notable institutional backers of Vor Biopharma Inc. include TCG Crossover Management, LLC, RA Capital Management, L.P., FCPM III Services B.V., according to Nexqual as of June 10, 2026 at 03:33 UTC.
Active Investors
| Investor | Stake |
|---|---|
| TCG Crossover Management, LLC | 10.47% |
| RA Capital Management, L.P. | 9.97% |
| FCPM III Services B.V. | 7.6% |
| Venrock Adviser, LLC | 5.61% |
| Frazier Life Sciences Management, L.P. | 4.69% |
| Caligan Partners, LP | 3.55% |
| Great Point Partners LLC | 3.23% |
| Paradigm Biocapital Advisors LP | 3.23% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.24% |
Source: Nexqual, June 10, 2026 at 03:33 UTC.
From Vor Biopharma Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases.
- The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
- It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IMCR | Immunocore Holdings plc | USD 28.52 | ▲ 0.81% |
| CGEM | Cullinan Therapeutics, Inc. | USD 13.18 | ▼ 2.44% |
| DSGN | Design Therapeutics, Inc. | USD 10.55 | ▼ 0.94% |
| BCAB | BioAtla, Inc. | USD 3.44 | ▲ 3.3% |
| SANA | Sana Biotechnology, Inc. | USD 2.82 | ▲ 5.22% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:33 UTC. This page is informational and not investment advice.